Kriya Therapeutics is developing gene therapies for ophthalmology, neurology and metabolic diseases. Despite diversifying to various disease indications, Kriya is using the same principles to create accessible, specific and effective one-time gene therapies to address common diseases. Kriya’s lead compounds across ophthalmology, neurology and metabolic are all currently in preclinical stages and are employing adeno-associated viruses (AAV) as their delivery modality. For example, Kriya’s approach to treat dry age-related macular degeneration, KRIYA-825, is an AAV gene therapy that encodes a fusion protein to inhibit complement C3 and C5, with the aim of slowing lesion growth and vision loss.

Kriya Therapeutics

Founded: 2019
Location: Redwood City, CA
Employee range: 50 - 200
Clinical stage: RD
Therapy area: Metabolic disorders
Drug types: NEU, OPH
Lead product: Undisclosed
Funding: $270M C May 2022; $100M B Jul 2021; $80M A May 2020

Drug notes:

About:

Jobs: